60 results
6-K
EX-99.3
CALT
Calliditas Therapeutics AB
25 Apr 24
Current report (foreign)
4:06pm
was a global, Phase 3, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of Nefecon 16 mg once daily … patients, irrespective of whether they had previously been treated with Nefecon or with placebo. The safety data after 9 months of treatment
6-K
EX-99.1
CALT
Calliditas Therapeutics AB
25 Apr 24
Current report (foreign)
4:06pm
Proteinuria (UPCR) at 24 months consisting of two readouts. An interim readout of effi-cacy and safety was conducted after 200 patients had been treated for 9 … treatment effect during the 15 month follow-up period off treatment. Safety Profile: The results indicated that Nefecon was generally well-tolerated
6-K
EX-99.2
bznl3h9oek jtx
21 Feb 24
Calliditas Year-end report, January – December 2023
4:05pm
6-K
EX-99.1
0tdzjorxjio u1oci2j
8 Jan 24
Calliditas Therapeutics appoints Maria Törnsén as President North America
8:28am
6-K
EX-99.1
o7qzw
20 Dec 23
Current report (foreign)
5:13pm
6-K
EX-99.1
rjiunc4e 1gpv86
30 Nov 23
Current report (foreign)
4:05pm
6-K
EX-99.1
m41l5z 3mp0su2a79
7 Nov 23
Interim Report January – September 2023 Q3
4:05pm
6-K
EX-99.1
akp945x2vnds
18 Aug 23
FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy
4:05pm
6-K
EX-99.2
ehfvskfcupu5b30
17 Aug 23
Filing for full approval of TARPEYO
4:05pm
6-K
EX-99.1
eamusaasv
17 Aug 23
Filing for full approval of TARPEYO
4:05pm
6-K
EX-99.1
r84pwm1x8x1
21 Jun 23
Current report (foreign)
4:05pm
6-K
EX-99.1
6jokftl
16 May 23
Current report (foreign)
4:05pm
6-K
EX-99.1
lq30r4xkjez9bdbqz90p
28 Apr 23
Current report (foreign)
4:05pm
6-K
EX-99.1
h3cgw3ej
14 Nov 22
Current report (foreign)
5:25pm
6-K
EX-99.1
vvweqol93qx9d j5ut1
19 Aug 22
Interim Report January 1ST – June 30TH 2022
7:55am